Transfer is a property of treated skin, not of a brand. Any topical testosterone creates a surface with drug on it, and drug on a surface can move to whoever touches it.
The consequences are documented at the highest level of regulatory seriousness. Testosterone gel carries an FDA boxed warning describing virilization in secondarily exposed children — enlargement of the penis or clitoris, pubic hair development, increased erections and libido, aggressive behaviour, and advanced bone age. Most signs regressed once exposure stopped; in a few cases enlarged genitalia did not fully return to age-appropriate size and bone age remained modestly advanced.[1]
The pharmaceutical-science literature records the same independently: specific incidences of secondary transfer of gels to children, with unwanted effects including precocious puberty.[2]
The variables that actually matter
If transfer is universal to the category, the useful question is what modulates it. Four things:
How much drug is on the surface. More residue, more available to transfer.
Over how large an area. A bigger treated surface is a bigger contact risk.
For how long before it is absorbed and dry. The window between application and dry is the exposure window.
Whether the site can be covered. The label's precaution is to cover the application site with clothing once the gel has dried.[1]
Those are formulation and application-behaviour variables. They are the honest axis on which topical products differ.
Why this applies to sprays too
It does, and saying otherwise would be exactly the kind of claim this hub does not make.
A metered transdermal spray is still a topical: it deposits testosterone on skin, and that skin can contact another person. The published pharmacokinetic work on the spray platform Keen uses is set out in the published clinical evidence — and the transfer precautions apply in full. Wash hands after applying, let the site dry before skin-to-skin contact, keep it covered.
Nothing about any formulation removes the need to ask who else is in the household.
The clinical consequence
Household composition is clinical information. Young children at home, or a partner who is pregnant or may become pregnant, belong in the conversation about which formulation to use — and the Endocrine Society guideline explicitly lists formulation-specific adverse effects among the factors to weigh.[3]
For topical testosterone, this is that factor.
Frequently asked questions
Is transfer avoidable? Largely, by following the labelled precautions — handwashing, drying time, covering the site.[1]
Do sprays transfer less than gels? The variables above determine it, and this page does not claim a ranking. The precautions apply to both.
What should I watch for in a child? Early pubic hair, genital enlargement, unusual aggression. Seek medical attention and mention the exposure.
Does it affect adult partners? The precautions name children and women in relation to contact with unwashed or unclothed application sites.[1]
Next in this series
If transfer is the constraint, the engineering question becomes how little you can leave on the skin and still deliver a dose.
Continue with the transdermal spray difference.
References
3 sources
- U.S. Food and Drug Administration. AndroGel (testosterone gel) 1% — prescribing information, including BOXED WARNING: secondary exposure to testosterone. Reference ID 021015s044. 2019. accessdata.fda.gov
- Hadgraft J, Lane ME. Transdermal delivery of testosterone. Eur J Pharm Biopharm. 2015;92:42–48. doi:10.1016/j.ejpb.2015.02.015 · PMID 25709060
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
Practical questions about membership, labs and using the spray are answered in the Learn Hub FAQ.